ABIVAX Société Anonyme (EPA: ABVX)
France
· Delayed Price · Currency is EUR 7.85
-0.10 (-1.26%)
Dec 2, 2024, 5:35 PM CET
ABIVAX Société Anonyme Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases.
The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Marc M. de Garidel |
Contact Details
Address: 7-11 boulevard Haussmann Paris, 75009 France | |
| Phone | 33 1 53 83 09 63 |
| Website | abivax.com |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0012333284 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel M.B.A. | Chief Executive Officer and Director |
| Dr. Philippe Pouletty M.D., Ph.D. | Founder and Director |
| Didier Blondel | EVice President, Chief Financial Officer and Board Secretary |
| Didier Scherrer Ph.D. | Chief Scientific Officer |
| Patrick Malloy | Senior Vice President of Investor Relations |
| Ida Hatoum | Chief People and Compliance Officer |
| Pierre Courteille M.B.A. | Chief Business Officer |
| Jerome Denis Ph.D. | Executive Vice President of Process Development and Manufacturing |
| Ana Sharma M.P.H. | Vice President and Global Head of Quality |
| Hema Keshava | Senior Vice President of Finance |